Abstract
Coronary heart disease is the leading cause of mortality worldwide, affecting millions of men and women every year. Elucidation of key signaling factors and their pathways are critical for understanding and developing novel therapeutic targets for protection of the myocardium from ischemia. EGR-1, an immediate early gene and a zinc finger transcription factor plays critical role in various cardiovascular patho-biological processes. This article reviews the growing evidence implicating EGR-1 pathway in myocardial ischemia/reperfusion, cardiac hypertrophy and other cardiovascular complications like atherosclerosis.
Keywords: Atherosclerosis, EGR-1, ischemia/reperfusion injury, myocardial cell death, myocardial infarction, oxidative stress, vascular inflammation.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Volume: 12 Issue: 2
Author(s): Nirupama Ramadas, Barathi Rajaraman, Ashok A. Kuppuswamy and Srinivasan Vedantham
Affiliation:
Keywords: Atherosclerosis, EGR-1, ischemia/reperfusion injury, myocardial cell death, myocardial infarction, oxidative stress, vascular inflammation.
Abstract: Coronary heart disease is the leading cause of mortality worldwide, affecting millions of men and women every year. Elucidation of key signaling factors and their pathways are critical for understanding and developing novel therapeutic targets for protection of the myocardium from ischemia. EGR-1, an immediate early gene and a zinc finger transcription factor plays critical role in various cardiovascular patho-biological processes. This article reviews the growing evidence implicating EGR-1 pathway in myocardial ischemia/reperfusion, cardiac hypertrophy and other cardiovascular complications like atherosclerosis.
Export Options
About this article
Cite this article as:
Ramadas Nirupama, Rajaraman Barathi, Kuppuswamy A. Ashok and Vedantham Srinivasan, Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (2) . https://dx.doi.org/10.2174/1871525713666150123152131
DOI https://dx.doi.org/10.2174/1871525713666150123152131 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science Metabolic Effects of a Diet with Inulin-Enriched Pasta in Healthy Young Volunteers
Current Pharmaceutical Design The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era
Current Drug Metabolism PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes
Current Drug Discovery Technologies Exploring the Management of Statin Intolerant Patients: 2016 and Beyond
Current Vascular Pharmacology Inflammatory Responses to Respiratory Syncytial Virus (RSV) Infection and the Development of Immunomodulatory Pharmacotherapeutics
Current Medicinal Chemistry Microbial Metabolomics
Current Genomics Cell Therapy for Myocardial Regeneration
Current Molecular Medicine Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research Novel Therapeutic Targets for Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Ivabradine: A Current Overview
Current Clinical Pharmacology Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design